Olema Pharmaceuticals (OLMA) COO/CFO reports 2 stock sales on Form 4

Rhea-AI Filing Summary

Olema Pharmaceuticals, Inc. chief operating and financial officer Shane William Charles Kovacs reported selling company common stock in two open-market transactions. On January 13, 2026, he sold 3,822 shares at a weighted average price of $28.01, within a price range of $28.00 to $28.03. On January 15, 2026, he sold 100,000 shares at a weighted average price of $28.73, within a price range of $28.50 to $29.18.

Following these transactions, Kovacs directly owned 139,727 shares of Olema Pharmaceuticals common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kovacs Shane William Charles

(Last) (First) (Middle)

C/O OLEMA PHARMACEUTICALS, INC.

780 BRANNAN ST

(Street)

SAN FRANCISCO CA 94103

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Olema Pharmaceuticals, Inc. [ OLMA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CH. OPERATING & FINANCIAL OFF.

3. Date of Earliest Transaction (Month/Day/Year)
01/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/13/2026		S		3,822	D	$28.01(1)	239,727	D
Common Stock	01/15/2026		S		100,000	D	$28.73(2)	139,727	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The weighted average sale price for the transaction reported was $28.01, and the range of prices were between $28.00 and $28.03. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

2. The weighted average purchase price for the transaction reported was $28.73, and the range of prices were between $28.50 and $29.18. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased at each separate price will be provided.

	/s/ Shane Kovacs	01/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider stock transactions did Olema Pharmaceuticals (OLMA) report in this Form 4?

The Form 4 reports that officer Shane William Charles Kovacs sold Olema Pharmaceuticals common stock in two transactions: 3,822 shares on January 13, 2026 and 100,000 shares on January 15, 2026, both coded as open-market sales.

Who is Shane Kovacs in relation to Olema Pharmaceuticals (OLMA)?

Shane William Charles Kovacs is an officer of Olema Pharmaceuticals, Inc., serving as the company’s Chief Operating & Financial Officer, as indicated in the filing.

How many Olema Pharmaceuticals (OLMA) shares did Shane Kovacs own after these January 2026 sales?

After the reported transactions, Shane Kovacs directly owned 139,727 shares of Olema Pharmaceuticals common stock, according to the Form 4.

At what prices were the Olema Pharmaceuticals (OLMA) shares sold in the January 2026 insider trades?

The January 13, 2026 transaction had a weighted average sale price of $28.01, with prices ranging from $28.00 to $28.03. The January 15, 2026 transaction had a weighted average price of $28.73, with prices ranging from $28.50 to $29.18.

Were the January 2026 OLMA insider transactions executed in multiple price tranches?

Yes. The filing states that the January 13, 2026 sale was executed at prices between $28.00 and $28.03, and the January 15, 2026 transaction was executed at prices between $28.50 and $29.18, with weighted average prices disclosed for each date.

Are Shane Kovacs’ Olema Pharmaceuticals (OLMA) holdings reported as direct or indirect ownership?

The Form 4 identifies the reported Olema Pharmaceuticals common stock holdings and transactions for Shane Kovacs as direct (D) ownership, with no separate indirect ownership nature specified.